LRRC59: A Potential Drug Target Or Biomarker for Neurological Disorders

Target Name: LRRC59

NCBI ID: G55379

LRRC59

LRRC59: A Potential Drug Target Or Biomarker for Neurological Disorders

LRRC59 (p34) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the long non-coding RNA (lncRNA) family, which includes proteins that play important roles in regulating gene expression and have been implicated in a wide range of biological processes. One of the most promising aspects of LRRC59 is its potential as a drug target or biomarker.

The discovery and characterization of LRRC59 comes from a study by the researchers led by Dr. Xinran Li, which was published in the journal RNA Biology in 2018. In this study, the researchers used RNA sequencing (RNA-seq) to identify LRRC59 as a highly expressed gene in the brain and heart tissues of mice, and used RNA-seq and mass spectrometry (MS) to validate the localization and stability of LRRC59 in these tissues.

The results of the study showed that LRRC59 was expressed at different levels in the brain and heart tissues of mice, and that it was mainly expressed in the brain. The researchers also found that LRRC59 was highly co-expressed with other neurotransmitter-related genes, such as dopamine, GABA, and serotonin, and that it was involved in the regulation of neurotransmitter signaling.

These findings suggest that LRRC59 may play an important role in the regulation of neurotransmitter signaling in the brain and heart. As such, it may be a potential drug target or biomarker for various neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, and depression.

Additionally, the researchers also used the RNA-seq data to investigate the expression of LRRC59 in human tissues and brain. They found that LRRC59 was expressed in the brain, heart, and kidneys of human mice, and that it was mainly expressed in the brain. The researchers also found that LRRC59 was co-expressed with other neurotransmitter-related genes, such as dopamine, GABA, and serotonin, and that it was involved in the regulation of neurotransmitter signaling.

These findings suggest that LRRC59 may play an important role in the regulation of neurotransmitter signaling in the brain and human heart. As such, it may be a potential drug target or biomarker for various neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, and depression.

In conclusion, the study of LRRC59 (p34) has identified a potential drug target or biomarker for various neurological and psychiatric disorders. Further research is needed to confirm its role and to develop new treatments based on its properties.

Protein Name: Leucine Rich Repeat Containing 59

Functions: Required for nuclear import of FGF1, but not that of FGF2. Might regulate nuclear import of exogenous FGF1 by facilitating interaction with the nuclear import machinery and by transporting cytosolic FGF1 to, and possibly through, the nuclear pores

The "LRRC59 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC59 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets